ArticleThe Journal of antimicrobial chemotherapy2026
Antimicrobial activity of aztreonam/avibactam and molecular characterization of Enterobacterales not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam from US medical centres (2016-2024).
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundResistance to ceftazidime/avibactam and meropenem/vaborbactam has been increasing among carbapenem-resistant Enterobacterales (CRE) in US hospitals recently. We evaluated the activity of aztreonam/avibactam and comparators against isolates that were not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam and against MBL-producing Enterobacterales.
methodsA total of 80 927 Enterobacterales isolates were consecutively collected (one per patient) in 2016-2024 from 103 US medical centres and susceptibility tested by broth microdilution in a monitoring laboratory. Among those, 194 (0.24%) were not susceptible to ceftazidime/avibactam or meropenem/vaborbactam, 115 (0.14%) were not susceptible to both ceftazidime/avibactam and meropenem/vaborbactam, and 832 (1.0%) isolates were carbapenem resistant. These isolates were screened for carbapenemase (CBase) genes by WGS.
resultsAztreonam/avibactam was active against 91.9% of ceftazidime/avibactam-non-susceptible isolates (n = 160), 94.0% of meropenem/vaborbactam-non-susceptible isolates (n = 149), 98.1% of CRE and 98.4% of MBL producers (n = 125). Cefiderocol retained activity against 78.8% of ceftazidime/avibactam-non-susceptible isolates, 83.2% of meropenem/vaborbactam-non-susceptible isolates, 94.7% of CRE and 82.1% of MBL producers. A CBase was identified in 159 (82.0%) of isolates not susceptible to ceftazidime/avibactam or meropenem/vaborbactam and in 683 (80.1%) of CREs. NDM (n = 114; 58.8% of isolates) was the most common CBase type among isolates not susceptible to ceftazidime/avibactam or meropenem/vaborbactam. Notably, an MBL was identified in 36.1% (73/202) of CRE collected in 2023-2024.
conclusionsAztreonam/avibactam demonstrated potent activity against isolates not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam as well as against CRE isolates, including MBL producers. The activities of other β-lactamase inhibitor combinations and cefiderocol were adversely affected by the alarming increase of MBL producers in some US hospitals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.